Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
OvaScience (NASDAQ: OVAS) today provided a corporate update. The Company announced initial clinical data from its ongoing Phase 1 trial of OvaPrime in women with primary ovarian insufficiency (POI) and poor ovarian response (POR). In an interim safety analysis of the first 20 patients followed for six months post-egg precursor (EggPCSM) cell reintroduction, OvaPrime was generally safe and well-tolerated. OvaScience has decided to close enrollment in this Phase 1 study at 78 patients, for a modified intent-to-treat (mITT) population of 60, and to progress OvaPrime into a multi-center Phase 1b/2a trial in women with POI or POR…
Read the full article at: https://www.streetinsider.com/Corporate News/OvaScience (OVAS) Reports Update on Phase 1 Clinical Trial of OvaPrime; Announces Corporate Restructuring & Appoints James Lillie Ph.D. as Chief Scientific Officer/13649290.html